ID
22165
Description
The present pharmacokinetic study is designed to assess the pharmacokinetics of RSG XR as monotherapy in patients with mild Alzheimer's disease (AD) as such information will not be obtained from the current phase III trials . The study aims to enroll fourteen patients (seven of each APOE genotype). Each patient will receive a single oral dose of 4mg of RSG XR in the morning under fasted conditions and PK samples will be taken up to 36h. GSK Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT00688207?term=NCT00688207&rank=1
Lien
https://clinicaltrials.gov/ct2/show/NCT00688207?term=NCT00688207&rank=1
Mots-clés
Versions (3)
- 08/05/2017 08/05/2017 -
- 15/05/2017 15/05/2017 -
- 22/05/2017 22/05/2017 -
Téléchargé le
22 mai 2017
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY-NC 3.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Screening Clinical Chemistry Mild Alzheimer''s Disease to Assess the of Extended Release Formulation of Rosiglitazone NCT00688207 / GSK-AVA109941
Screening Clinical Chemistry Mild Alzheimer''s Disease to Assess the of Extended Release Formulation of Rosiglitazone NCT00688207 / GSK-AVA109941
Similar models
Screening Clinical Chemistry Mild Alzheimer''s Disease to Assess the of Extended Release Formulation of Rosiglitazone NCT00688207 / GSK-AVA109941
C0008000 (UMLS CUI-2)
C0008000 (UMLS CUI [2,1])
C0040223 (UMLS CUI [2,2])
C0015663 (UMLS CUI [1,2])
C2826772 (UMLS CUI-2)
C0008000 (UMLS CUI [1,2])
C0008000 (UMLS CUI [1,2])
C0008000 (UMLS CUI [1,2])